ScreenerHero

GLSIGreenwich LifeSciences, Inc.

NAS · US · Healthcare · Biotechnology · greenwichlifesciences.com
16.67USD+8.88%Mkt Cap: 244.69M $P/E: —

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap244.69M $
Enterprise Value215.85M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.36M $
Revenue/Share—
Last Price16.67 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.67
PEG—
EV/EBITDA-9.53
EV/Revenue—
P/S—
P/B42.65
EPS (TTM)-1.41
EPS (Forward)-0.82
52W Range
7.78034% of range34.10
52W High34.10 USD
52W Low7.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-5480.55%
ROA-313.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.91M $
CapEx (TTM)—
FCF Margin—
FCF Yield-1.37%
Net Debt-8.88M $
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity—
Current Ratio1.54
Quick Ratio1.54
Book Value/Sh0.3590 USD
Cash/Share0.6050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)57.00 USD
Upside (mean)+241.9%
Target Range45.00 USD – 69.00 USD
$45.00+241.9% to mean$69.00
# Analysts2
Ownership
Shares Out.14.68M
Float7.38M
Insiders47.91%
Institutions12.25%
Short Interest
Short Ratio8.9d
Short % Float20.14%
Short % Out.10.50%
Shares Short1.54M
Short (prev mo.)1.46M
Technical
SMA 5018.14 (-8.1%)
SMA 20020.66 (-19.3%)
Beta1.45
S&P 52W Chg18.16%
Avg Vol (30d)154.10K
Avg Vol (10d)124.66K
Technical Indicators
RSI (14)51.6
MACD-0.2565
MACD Signal-0.7383
MACD Hist.+0.4819
BB Upper18.00 USD
BB Middle14.95 USD
BB Lower11.89 USD
BB Width40.83%
ATR (14)1.570 USD
Vol Ratio (20d)1.45x